{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:48:21Z","timestamp":1787237301329,"version":"build-2736575974"},"reference-count":120,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Mast cells (MCs) are immune cells distributed in many organs and tissues and involved in the pathogenesis of allergic and inflammatory diseases as a major source of pro-inflammatory and vasoactive mediators. MC-related disorders are heterogeneous conditions characterized by the proliferation of MC within tissues and\/or MC hyper-reactivity that leads to the uncontrolled release of mediators. MC disorders include mastocytosis, a clonal disease characterized by tissue MC proliferation, and MC activation syndromes that can be primary (clonal), secondary (related to allergic disorders), or idiopathic. Diagnosis of MC disorders is difficult because symptoms are transient, unpredictable, and unspecific, and because these conditions mimic many other diseases. Validation of markers of MC activation in vivo will be useful to allow faster diagnosis and better management of MC disorders. Tryptase, being the most specific MC product, is a widely used biomarker of proliferation and activation. Other mediators, such as histamine, cysteinyl leukotrienes, and prostaglandin D2, are unstable molecules and have limitations in their assays. Surface MC markers, detected by flow cytometry, are useful for the identification of neoplastic MC in mastocytosis but, so far, none of them has been validated as a biomarker of MC activation. Further studies are needed to identify useful biomarkers of MC activation in vivo.<\/jats:p>","DOI":"10.3390\/ijms24087071","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T02:57:08Z","timestamp":1681268228000},"page":"7071","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Secretory and Membrane-Associated Biomarkers of Mast Cell Activation and Proliferation"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4187-6477","authenticated-orcid":false,"given":"Roberta","family":"Parente","sequence":"first","affiliation":[{"name":"Division of Allergy and Clinical Immunology, University of Salerno, 84081 Baronissi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7492-6848","authenticated-orcid":false,"given":"Valentina","family":"Giudice","sequence":"additional","affiliation":[{"name":"Division of Hematology and Transplant Center, University of Salerno, 84081 Baronissi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cardamone","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, University of Salerno, 84081 Baronissi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Serio","sequence":"additional","affiliation":[{"name":"Division of Hematology and Transplant Center, University of Salerno, 84081 Baronissi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5861-8984","authenticated-orcid":false,"given":"Carmine","family":"Selleri","sequence":"additional","affiliation":[{"name":"Division of Hematology and Transplant Center, University of Salerno, 84081 Baronissi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7318-2093","authenticated-orcid":false,"given":"Massimo","family":"Triggiani","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, University of Salerno, 84081 Baronissi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/978-1-4419-9533-9_1","article-title":"Mast cells biology: Introduction and overview","volume":"716","author":"Gilfillan","year":"2011","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"10743","DOI":"10.7150\/thno.46719","article-title":"Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich\u2019s visions to precision medicine concepts","volume":"10","author":"Valent","year":"2020","journal-title":"Theranostics"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2011.09.007","article-title":"The role of mast cells in allergic inflammation","volume":"106","author":"Amin","year":"2012","journal-title":"Respir. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1369\/0022155414545334","article-title":"Mast cell function: A new vision of an old cell","volume":"62","author":"Jamur","year":"2014","journal-title":"J. Histochem. Cytochem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_6","first-page":"498","article-title":"Mast cell activation syndrome: Tools for diagnosis and differential diagnosis","volume":"8","author":"Weiler","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.iac.2006.05.008","article-title":"Flow cytometric analysis of normal and neoplastic mast cells: Role in diagnosis and follow-up of mast cell disease","volume":"26","author":"Escribano","year":"2006","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jaci.2017.06.007","article-title":"Mast cell activation syndromes","volume":"140","author":"Akin","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.clinthera.2013.04.001","article-title":"Expanding spectrum of mast cell activation disorders: Monoclonal and idiopathic mast cell activation syndromes","volume":"35","author":"Picard","year":"2013","journal-title":"Clin. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","article-title":"Updated diagnostic criteria and classification of mast cell disorders. A consensus proposal","volume":"5","author":"Valent","year":"2021","journal-title":"Hemasphere"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.iac.2006.05.005","article-title":"Mast cell mediators in allergic inflammation and mastocytosis","volume":"26","author":"Castells","year":"2006","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: Recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.2019000932","article-title":"New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis","volume":"135","author":"Reiter","year":"2020","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/all.14248","article-title":"Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification","volume":"75","author":"Trizuljak","year":"2020","journal-title":"Allergy"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000048188","article-title":"Mastocytosis: Mediator related signs and symptoms","volume":"127","author":"Castells","year":"2002","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1182\/blood-2005-09-3610","article-title":"De novo synthesis of early growth response factor-1 is required for the full responsiveness of mast cells to produce TNF and IL-13 by IgE and antigen stimulation","volume":"107","author":"Li","year":"2006","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/1523-1747.ep12327815","article-title":"Production of interleukin-6 by human mast cells and basophilic cells","volume":"106","author":"Moller","year":"1996","journal-title":"J. Investig. Dermatol."},{"key":"ref_20","first-page":"331","article-title":"Interleukin-6 and mast cells","volume":"23","author":"Conti","year":"2002","journal-title":"Allergy Asthma. Proc."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/1744666X.2019.1596800","article-title":"Recent advances in our understanding of mast cell activation\u2014Or should it be mast cell mediator disorders?","volume":"15","author":"Theoharides","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Valent, P., Akin, C., Nedoszytko, B., Bonadonna, P., Hartmann, K., Niedoszytko, M., Brockow, K., Siebenhaar, F., Triggiani, M., and Arock, M. (2020). Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239030"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jaci.2019.08.023","article-title":"AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management","volume":"144","author":"Weiler","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","article-title":"Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome","volume":"7","author":"Valent","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000501079","article-title":"Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome","volume":"180","author":"Valent","year":"2019","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/all.15032","article-title":"EAACI guidelines: Anaphylaxis (2021 updates)","volume":"77","author":"Muraro","year":"2022","journal-title":"Allergy"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.iac.2018.04.003","article-title":"Hereditary alpha tryptasemia: Genotyping and associated clinical features","volume":"38","author":"Lyons","year":"2019","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.2020006157","article-title":"Hereditary alpha tryptasemia is a valid genetic biomarker for severe mediator related symptoms in mastocytosis","volume":"137","author":"Greiner","year":"2021","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jaci.2022.09.038","article-title":"Disease correlates and clinical relevance of hereditary alpha-tryptasemia in patients with systemic mastocytosis","volume":"151","author":"Sordi","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11882-021-01010-1","article-title":"Hereditary alpha-tryptasemia: A commonly inherited modifier of anaphylaxis","volume":"21","author":"Wu","year":"2021","journal-title":"Curr. Allergy Asthma. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.iac.2018.04.011","article-title":"Mast cell mediators of significance in clinical practice in mastocytosis","volume":"28","author":"Butterfield","year":"2018","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000503964","article-title":"Survey of Mast Cell Mediator Levels from Patients Presenting with Symptoms of Mast Cell Activation","volume":"181","author":"Butterfield","year":"2020","journal-title":"Int. Arch. Allergy Clin. Immunol."},{"key":"ref_33","first-page":"2348","article-title":"Mast cell activation syndromes\u2014Evaluation of current diagnostic criteria and laboratory tools in clinical practice (Review)","volume":"20","author":"Leru","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.anai.2010.08.005","article-title":"The basics of histamine biology","volume":"106","author":"Lieberman","year":"2011","journal-title":"Ann. Allergy Asthma. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.anai.2015.07.019","article-title":"Anaphylaxis\u2014A practice parameter update 2015","volume":"115","author":"Lieberman","year":"2015","journal-title":"Ann. Allergy Asthma. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1067\/mai.2000.107600","article-title":"Histamine and tryptase levels in patients with acute allergic reactions: An emergency department-based study","volume":"106","author":"Lin","year":"2000","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0002-9343(89)80398-5","article-title":"Analysis of plasma histamine levels \u2028in patients with mast cell disorders","volume":"87","author":"Friedman","year":"1989","journal-title":"Am. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jaci.2009.08.025","article-title":"Anaphylaxis: Recent advances in assessment and treatment","volume":"124","author":"Simons","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1398-9995.2012.02809.x","article-title":"Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis \u2028without skin lesions","volume":"67","author":"Kluin","year":"2012","journal-title":"Allergy"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1046\/j.1365-2230.2002.01072.x","article-title":"Urinary N-methylhistamine as an indicator of bone marrow involvement in mastocytosis","volume":"27","author":"Oranje","year":"2002","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/all.12668","article-title":"Urinary 11\u03b2-PGF2\u03b1 and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders","volume":"70","author":"Divekar","year":"2015","journal-title":"Allergy"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/imr.12639","article-title":"Biomarkers for evaluation of mast cell and basophil activation","volume":"282","author":"Kabashima","year":"2018","journal-title":"Immunol. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.molimm.2014.04.001","article-title":"Human mast cell tryptase in biology and medicine","volume":"63","author":"Vitte","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0145-2126(01)00020-0","article-title":"Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders","volume":"25","author":"Schwartz","year":"2001","journal-title":"Leuk. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.iac.2006.05.010","article-title":"Diagnostic Value of Tryptase in Anaphylaxis and Mastocytosis","volume":"26","author":"Schwartz","year":"2006","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1254\/jphs.FMJ04005X3","article-title":"Physiology and pathophysiology of proteinase-activated receptors (PARs): Role of tryptase\/PAR-2 in vascular endothelial barrier function","volume":"97","author":"Itoh","year":"2005","journal-title":"J. Pharmacol. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1084\/jem.20190701","article-title":"Impact of naturally forming human \u03b1\/\u03b2 tryptase heterotetramers in the pathogenesis of hereditary \u03b1 tryptasemia","volume":"216","author":"Quang","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1080\/10428190290021470","article-title":"Serum tryptase measurement in patients with myelodysplastic syndromes","volume":"43","author":"Sperr","year":"2002","journal-title":"Leuk. Lymphoma."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jaci.2012.08.016","article-title":"Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis","volume":"131","author":"Vadas","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000339749","article-title":"Usefulness and limitations of sequential serum tryptase for the diagnosis of anaphylaxis in 102 patients","volume":"160","author":"Cardona","year":"2013","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000059404","article-title":"Serum tryptase levels in patients with mastocytosis: Correlation with mast cell burden and implication for defining the category of disease","volume":"128","author":"Sperr","year":"2002","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/ejh.12128","article-title":"Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis","volume":"91","author":"Kristensen","year":"2013","journal-title":"Eur. J. Haematol"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","article-title":"International prognostic scoring system for mastocytosis (IPSM): A retrospective cohort study","volume":"6","author":"Sperr","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ajh.26118","article-title":"Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management","volume":"96","author":"Pardanani","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.3109\/10428194.2012.763121","article-title":"Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis","volume":"54","author":"Server","year":"2013","journal-title":"Leuk. Lymphoma."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jaci.2012.12.1578","article-title":"Higher mast cell load decreases the risk of hymenoptera venom-induced anaphylaxis in patients with mastocytosis","volume":"132","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","article-title":"Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness","volume":"101","author":"Klion","year":"2003","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaci.2021.08.007","article-title":"Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis","volume":"149","author":"Mateya","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/ACI.0000000000000184","article-title":"Markers of anaphylaxis, beyond tryptase","volume":"15","author":"Cardona","year":"2015","journal-title":"Curr. Opin. Allergy Clin. Immunol"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00414-005-0524-1","article-title":"Usefulness of serum mast cell-specific chymase levels for postmortem diagnosis of anaphylaxis","volume":"119","author":"Nishio","year":"2015","journal-title":"Int. J. Legal. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5770","DOI":"10.4049\/jimmunol.0900127","article-title":"Alpha 2-macroglobuline capture allows detection of mast cell chymase in serum and creates a reservoir of angiotensin II-generating activity","volume":"182","author":"Raymond","year":"2009","journal-title":"J. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1016\/j.jaip.2020.02.021","article-title":"The Utility of Measuring Urinary Metabolites of Mast Cell Mediators in Systemic Mastocytosis and Mast Cell Activation Syndrome","volume":"8","author":"Butterfield","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jaci.2015.07.001","article-title":"Serum levels of 9alpha, 11beta PGF2 and cysteinyl leukotrienes are useful biomarkers of anaphylaxis","volume":"137","author":"Nassiri","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000144042","article-title":"Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production","volume":"147","author":"Butterfield","year":"2008","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaip.2014.06.011","article-title":"Mast cell activation syndrome: Improved identification by combined determinations of serum tryptase and 24-hour urine 11beta-prostaglandin2alpha","volume":"2","author":"Ravi","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/biof.1883","article-title":"Platelet activating factor (PAF): A mediator of inflammation","volume":"48","author":"Upton","year":"2022","journal-title":"Biofactors"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.anai.2016.05.003","article-title":"The platelet-activating factor pathway in food allergy and anaphylaxis","volume":"117","author":"Vadas","year":"2016","journal-title":"Ann. Allergy Asthma. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa070030","article-title":"Platelet-activating factor, PF acetylhydrolase, and severe anaphylaxis","volume":"358","author":"Vadas","year":"2008","journal-title":"N. Eng. J. Med."},{"key":"ref_69","first-page":"391","article-title":"A Occurrence of platelet-activating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosis","volume":"77","author":"Macpherson","year":"1989","journal-title":"Clin. Exp. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/ni0208-113","article-title":"The cysteinyl leukotrienes: Where do they come from? What are they? Where are they going?","volume":"9","author":"Austen","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.prostaglandins.2010.03.003","article-title":"Increased leukotriene E4 excretion in systemic mastocytosis","volume":"92","author":"Butterfield","year":"2010","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3324\/haematol.2019.234864","article-title":"KIT D816V and the cytokine storm in mastocytosis: Production and role of interleukin-6","volume":"105","author":"Valent","year":"2020","journal-title":"Haematologica"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000063858","article-title":"Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients","volume":"128","author":"Theoharides","year":"2002","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.clim.2005.01.011","article-title":"IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis","volume":"115","author":"Brockow","year":"2005","journal-title":"Clin. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/leu.2015.176","article-title":"Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression","volume":"30","author":"Mayado","year":"2015","journal-title":"Leukemia"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jaci.2012.11.008","article-title":"Serum Il-31 levels are increased in a subset of patients with mastocytosis and correlate with disease severity in adults patients","volume":"132","author":"Hartmann","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.iac.2014.01.008","article-title":"Flow cytometry in mastocytosis: Utility as a diagnostic and prognostic tool","volume":"34","author":"Teodosio","year":"2014","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/B978-0-12-385493-3.00014-0","article-title":"Immunophenotypic characterization of bone marrow mast cells in mastocytosis and other mast cell disorders","volume":"103","author":"Morgado","year":"2011","journal-title":"Methods Cell Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0145-2126(01)00050-9","article-title":"Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis","volume":"25","author":"Escribano","year":"2001","journal-title":"Leuk. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1155\/1998\/341340","article-title":"Immunophenotypic characterization of human bone marrow mast cells. A flow cytometric study of normal and pathological bone marrow samples","volume":"16","author":"Escribano","year":"1998","journal-title":"Annal. Cell. Pathol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1189\/jlb.5RU0614-296R","article-title":"The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis","volume":"97","author":"Teodosio","year":"2015","journal-title":"J. Leuk. Biol"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.iac.2018.04.012","article-title":"Bone marrow expression of mast cell disorders","volume":"38","author":"Henriques","year":"2018","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood.V91.8.2731.2731_2731_2736","article-title":"Indolent systemic mast cell disease in adults: Immunophenotypic characterization of bone marrow mast cells and its diagnostic implications","volume":"91","author":"Escribano","year":"1998","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.10.020","article-title":"Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes","volume":"125","author":"Teodosio","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaci.2015.05.008","article-title":"Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis","volume":"137","author":"Morgado","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/modpathol.2011.192","article-title":"Immunophenotyping in systemic mastocytosis diagnosis: \u2018CD25 positive\u2019 alone is more informative than the \u2018CD25 and\/or CD2\u2032 WHO criterion","volume":"25","author":"Morgado","year":"2012","journal-title":"Mod. Pathol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/modpathol.2010.224","article-title":"Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis","volume":"24","author":"Sotlar","year":"2011","journal-title":"Mod. Pathol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1006\/smim.1998.0156","article-title":"CD30, expression and function in health and disease","volume":"10","author":"Horie","year":"1998","journal-title":"Semin. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1182\/blood.V126.23.1616.1616","article-title":"Correlation of CD30 Expression on Neoplastic Mast Cells in Systemic Mastocytosis Assessed By Immunohistochemistry Versus Multiparameter Flow Cytometry and Correlation to Clinical Parameters","volume":"126","author":"Bellos","year":"2015","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/his.12221","article-title":"CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis","volume":"63","author":"Morgado","year":"2013","journal-title":"Histopathology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood.V96.4.1267","article-title":"Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: Relationships to disease severity and bone marrow pathology","volume":"96","author":"Akin","year":"2000","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1038\/leu.2013.11","article-title":"Increased circulating IL-2R\u03b1 (CD25) predicts poor outcome in both indolent and aggressive forms of mastocytosis: A comprehensive cytokine-phenotype study","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.4049\/jimmunol.1202323","article-title":"The tetraspanin CD63 is required for efficient IgE-mediated mast cell degranulation and anaphylaxis","volume":"191","author":"Kraft","year":"2013","journal-title":"J. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/cyto.a.20068","article-title":"LAMP-1 and LAMP-2, but not LAMP-3, are reliable markers for activation-induced secretion of human mast cells","volume":"61","author":"Gruzkau","year":"2004","journal-title":"Cytom. Part A J. Int. Soc. Anal. Cytol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jaci.2018.01.043","article-title":"Mast cell activation test in the diagnosis of allergic disease and anaphylaxis","volume":"142","author":"Bahri","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40413-016-0094-3","article-title":"Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases","volume":"9","author":"Metcalfe","year":"2016","journal-title":"World Allergy Organ. J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000048183","article-title":"Abnormal expression of CD antigens in mastocytosis","volume":"127","author":"Escribano","year":"2002","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Lazki-Hagenbach, P., Ali, H., and Sagi-Eisemberg, R. (2021). Authentic and Ectopically Expressed MRGPRX2 Elicit Similar Mechanisms to Stimulate Degranulation of Mast Cells. Cells, 10.","DOI":"10.3390\/cells10020376"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1172\/JCI85538","article-title":"Different activation signals induce distinct mast cell degranulation strategies","volume":"126","author":"Gaudenzio","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.bbrc.2006.08.177","article-title":"Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors","volume":"349","author":"Tatemoto","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2014.05.004","article-title":"Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria","volume":"134","author":"Fujisawa","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jaci.2021.03.049","article-title":"Multifaceted MRGPRX2, New insight into the role of mast cells in health and disease","volume":"148","author":"Roy","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1111\/all.14791","article-title":"Interleukin-31, The \u201citchy\u201d cytokine in inflammation and therapy","volume":"76","author":"Datsi","year":"2021","journal-title":"Allergy"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaci.2020.08.027","article-title":"Mas-related G protein\u2013coupled receptor X2 and its activators in dermatologic allergies","volume":"147","author":"Kuhn","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaci.2016.04.051","article-title":"Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases","volume":"138","author":"Subramanian","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.jaip.2019.01.059","article-title":"Anaphylaxis to quinolones in mastocytosis: Hypothesis on the mechanism","volume":"7","author":"Goncalves","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.it.2017.01.008","article-title":"Positive and negative signals in mast cell activation","volume":"38","author":"Nilsson","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1182\/blood-2012-09-435057","article-title":"The CD300 molecules: An emerging family of regulators of the immune system","volume":"121","author":"Borrego","year":"2013","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4049\/jimmunol.175.12.7989","article-title":"The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast cells","volume":"175","author":"Bachelet","year":"2005","journal-title":"J. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1182\/blood-2005-07-2926","article-title":"The inhibitory receptor IRp60 (CD300a) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils","volume":"107","author":"Munitz","year":"2006","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/cyto.b.21003","article-title":"CD300a is expressed on human basophils and seems to inhibit IgE\/Fc\u03b5RI-dependent anaphylactic degranulation","volume":"82","author":"Sabato","year":"2012","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"27190","DOI":"10.1074\/jbc.M602359200","article-title":"Mast cell costimulation by CD226\/CD112 (DNAM-1\/Nectin-2): A novel interface in the allergic process","volume":"281","author":"Bachelet","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jaci.2006.04.031","article-title":"Abrogation of allergic reactions by a bispecific antibody fragment linking IgE to CD300a","volume":"117","author":"Bachelet","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.4049\/jimmunol.180.9.6064","article-title":"Suppression of normal and malignant kit signaling by a bispecific antibody linking kit with CD300a","volume":"180","author":"Bachelet","year":"2008","journal-title":"J. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"7662","DOI":"10.1074\/jbc.M112.434746","article-title":"Human CD300C delivers an Fc receptor-\u03b3-dependent activating signal in mast cells and monocytes and differs from CD300A in ligand recognition","volume":"288","author":"Takahashi","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jaci.2013.08.008","article-title":"Sphingomyelin and ceramide are physiological ligands for human LMIR3\/CD300f, inhibiting Fc\u03b5RI-mediated mast cell activation","volume":"133","author":"Izawa","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.4049\/jimmunol.1600614","article-title":"Mast Cell Degranulation Is Accompanied by the Release of a Selective Subset of Extracellular Vesicles That Contain Mast Cell-Specific Proteases","volume":"197","author":"Arkesteijn","year":"2016","journal-title":"J. Immunol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e968","DOI":"10.1073\/pnas.1521230113","article-title":"Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes","volume":"113","author":"Kowal","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.molimm.2014.01.018","article-title":"Mast cell progenitors: Origin, development and migration to tissues","volume":"63","author":"Dahlin","year":"2015","journal-title":"Mol. Immunol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/8\/7071\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:14:00Z","timestamp":1760123640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/8\/7071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":120,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ijms24087071"],"URL":"https:\/\/doi.org\/10.3390\/ijms24087071","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,11]]}}}